KEY DETAILS
HuffPost cites a Gallup poll finding that 11% of American adults report taking GLP-1 medications, up from 3% in 2024.
The New York Post reports that Hershey has a protein powder coming out in January, aimed at consumers who have soured on sweets.
EUROPE SAYS reports that Dr Reddy's generic Ozempic brands Obeda Pro and Obeda Plus, made by Hetero Labs, began appearing in the Indian market in late July, after Obeda injection was recalled in July.
Newsweek reports that Mayo Clinic researchers found GLP-1 drugs were associated with a lower risk of dialysis and kidney transplantation in people with bipolar disorder and chronic kidney disease.
indiatoday.in reports that doctors say the science behind GLP-1 microdosing remains limited, with no established clinical definition.
HuffPost cites a Gallup poll finding that 11% of American adults report taking GLP-1 medications, up from 3% in 2024, as the outlet covered reactions to President Trump calling the drugs 'fat drugs.' The New York Post reports that Hershey has a protein powder coming out in January, aimed at consumers who have soured on sweets. And in India, EUROPE SAYS reports that Dr Reddy's generic Ozempic brands Obeda Pro and Obeda Plus began appearing in India in late July, after the July recall of Obeda injection.
HuffPost's own reporting adds context to that figure. The outlet reports that in a few instances, Trump referred to GLP-1 medications as 'fat drugs' during briefings about lowering drug prices. HuffPost notes that President Trump, who has taken steps to make GLP-1 medications cheaper, often seems to reduce them to an insult. Doctors and GLP-1 users responded to those comments in the piece.
On the business side, The New York Post reports that nearly 30% of obese US adults are expected to be on appetite-suppressing GLP-1 drugs by 2035, and that Hershey CEO Tanner wants to know how the company can innovate. The outlet also reports that the protein snack bar market is expected to go from $21.94 billion to $32.66 billion by 2031. The New York Post notes Hershey is also expanding its gum-and-mints division to accommodate consumers battling 'Ozempic breath,' described as the bad-breath side effect of the drug. According to Bloomberg, as cited by the outlet, Tanner has increased research and development spending by 25% since he came to Hershey last year.
Overseas, EUROPE SAYS reports that Dr Reddy's Laboratories has two additional generic Ozempic brands, Obeda Pro and Obeda Plus, according to product photographs and marketing materials reviewed by Reuters. The outlet reports that these products are made by a different manufacturer, Hetero Labs, than the original Obeda injectable, supplies of which were halted in July after Dr Reddy's discovered an impurity in the active ingredient. EUROPE SAYS notes that Obeda Pro and Obeda Plus began appearing in the market in late July, according to supply invoices reviewed by Reuters, and that Dr Reddy's sold about 442,000 units of generic semaglutide through September in India, according to research firm Pharmarack.
On the research side, a study looked at a narrower population. Newsweek reports that Mayo Clinic researchers found GLP-1 medications were associated with a lower risk of dialysis and kidney transplantation in people with bipolar disorder and chronic kidney disease. Study author Dr Balwinder Singh told Newsweek that the study provides the first evidence suggesting that, over the long term, GLP-1 receptor agonists may be renoprotective in that patient group. Singh also told the outlet that in the short term, starting a GLP-1 receptor agonist in patients taking lithium may increase the risk of lithium toxicity if lithium levels, renal function and hydration status are not carefully monitored.
Back on the consumer side, not every trend has that kind of research behind it. indiatoday.in reports that some users are experimenting with smaller-than-recommended doses of GLP-1 drugs to curb hunger, manage side effects and maintain weight loss. The outlet reports that doctors say the science behind microdosing remains limited, raising questions about its safety, effectiveness and long-term benefits. indiatoday.in notes that microdosing has no established clinical definition or standardised treatment protocol.
You can read the full reporting at HuffPost, the New York Post, EUROPE SAYS, Newsweek and indiatoday.in for more on each of these stories. Each outlet goes deeper into the details than a roundup can cover.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.